We performed a search of the PubMed database (January 1990January 2017) to review pertinent clinical trials of midostaurin. Food and Drug Administration in April 2017 for the treatment of FLT3-mutant AML. This paper reviews the current clinical evidence regarding Mido and its use in the induction and treatment of relapsed or refractory disease, and maintenance setting. Midostaurin is a first-generation FMS-like tyrosine kinase 3 (FLT3) inhibitor (TKI) that was approved by the U.S.
MIDOSTAURIN FREE CLINICAL TRIALS TRIAL
The clinical trial was conducted by Novartis in association with the Alliance for Clinical Trials in Oncology and its 13 contributing international co-operative groups.
The RATIFY study demonstrated significant improvements in overall survival, and in event-free survival, when Mido was added to standard chemotherapy in patients with newly diagnosed FLT3-mutated AML. Clinical trials on Rydapt (midostaurin) FDA approval of Rydapt was based on results obtained from a phase III clinical study known as RATIFY (CALGB 10603 Alliance). Mido is the first targeted therapy to demonstrate improved outcome, and as such it represents a game-changer. Midostaurin (Mido) is a multi-targeted tyrosine kinase inhibitor that potently inhibits kinase FLT3, other kinases including platelet-derived growth factor receptors α (PDGFR- α) and b (PDGFR- β), tyrosine-protein kinase Src, KIT receptor tyrosine kinase, and vascular endothelial growth factor receptor (VEGFR).
MIDOSTAURIN FREE CLINICAL TRIALS DRIVER
Mutation with internal tandem duplication of fms-like tyrosine kinase-3 (FLT3-ITD) is one of the two most common driver mutations in AML, the presence of which is associated with a poor outcome.
Clinical trials on Rydapt (midostaurin) FDA approval of Rydapt® was based on results obtained from a phase III clinical study known as RATIFY (CALGB 10603 Alliance). The drug is available in oral capsules with a 25mg dose. Acute myeloid leukemia (AML) is a highly heterogeneous disease. The drug regulates essential cell processes and breaks off cancer cells’ ability to grow and proliferate.
0 kommentar(er)
